NCT06833645 [18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease
| NCT ID | NCT06833645 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sichuan Provincial People's Hospital |
| Condition | Alzheimer's Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 280 participants |
| Start Date | 2024-05-10 |
| Primary Completion | 2025-02-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 280 participants in total. It began in 2024-05-10 with a primary completion date of 2025-02-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate the primary brain regions of precursors of Alzheimer's disease and Alzheimer's disease by novel molecular probe \[18F\]AV45(Aβ) and \[18F\]AV1451(Tau)PET/CT imaging. And the distribution of positive lesions in the brain area affecting the simple mental state examination and the Montreal Cognitive Assessment Scale in AD patients; It is expected to provide molecular imaging information for further study of the pathogenesis of AD. After clinical transformation, objective and quantitative positive diagnostic criteria for \[18F\]AV45 and \[18F\]AV1451PET/CT in the diagnosis of early Alzheimer's disease were established to avoid the defects of relying on the subjective experience of doctors and time-consuming diagnosis.
Eligibility Criteria
Inclusion Criteria: * Meet the MCI diagnostic criteria of Peterson in 2004; * The clinicaldementiarating Scale (CDR) score was 0.5; * Prominent memory loss may also be accompanied by impairment of other cognitive domains; * Insidious onset and slow progression; * Not at the level of dementia. AD entry criteria: * Meet the criteria for diagnosing dementia as described in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-R), Use the diagnostic criteria for AD from the National Institute of Neurology, Speech and Communication Disorders and Stroke - Alzheimer's Disease and Related Disorders (NINCDS-ADRDA) or the National Institute on Aging and Alzheimer's Disease Association (NIA-AA). * Clinical Dementia Rating Scale score was 1 point. Exclusion Criteria: * Patients with a history of stroke and focal neurological signs, and imaging findings consistent with small cerebral vascular disease (Fazekas score ≥2); * The presence of other neurological disorders that can cause brain dysfunction (e.g., depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, Normal facial pressure hydrocephalus); * The presence of other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.); * There is mental and neurological retardation. * There are other diseases that are known to cause cognitive impairment.
Contact & Investigator
Hao Wang
STUDY DIRECTOR
Sichuan Provincial People's Hospital
Frequently Asked Questions
Who can join the NCT06833645 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alzheimer's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06833645 currently recruiting?
Yes, NCT06833645 is actively recruiting participants. Contact the research team at 474556259@qq.com for enrollment information.
Where is the NCT06833645 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT06833645 clinical trial?
NCT06833645 is sponsored by Sichuan Provincial People's Hospital. The principal investigator is Hao Wang at Sichuan Provincial People's Hospital. The trial plans to enroll 280 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.